文献速递甲状腺疾病

转移性甲状腺未分化癌的挽救性仑伐替尼治疗

Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
PubMed 文献 · Thyroid · 2017-05-31

该回顾性分析纳入2015年Mayo Clinic收治的28例甲状腺未分化癌患者,其中3例(11%)转移性、ECOG体能状态2-3分的患者接受仑伐替尼治疗。2例获轻微缓解(转移灶在1-2个月内结构退缩),1例疾病稳定,无RECIST部分缓解;仑伐替尼开始后总生存分别为2、6、7个月。作者认为仑伐替尼可能对转移性甲状腺未分化癌有疾病修饰活性,但获益短暂、毒性突出,需临床试验进一步明确其效用。

要点

  • 3例转移性甲状腺未分化癌患者接受仑伐替尼挽救治疗,2例轻微缓解、1例疾病稳定,无RECIST部分缓解。
  • 仑伐替尼开始后总生存分别为2、6、7个月,获益短暂。
  • 疲劳和高血压突出,1例用药期间发生肺栓塞。

核心结论

  • 这项单中心初步经验提示,仑伐替尼可能对细胞毒性化疗难治的转移性甲状腺未分化癌具有一定疾病修饰活性,但观察到的获益短暂且毒性突出,需要临床试验来更好地明确仑伐替尼在晚期甲状腺未分化癌管理中的效用。

研究设计与样本

  • 回顾性分析,纳入2015年Mayo Clinic所有接受仑伐替尼治疗的甲状腺未分化癌患者。
  • 2015年共诊治28例甲状腺未分化癌患者,其中3例(11%)转移性疾病且ECOG体能状态2-3分的患者接受仑伐替尼治疗。

主要发现

  • 3例患者中2例为男性,甲状腺未分化癌诊断时年龄范围为57-84岁。
  • 3例患者均通过手术和/或联合放化疗实现成功的局部控制。
  • 仑伐替尼在转移性疾病进展时作为第二、第三或第四线治疗给予。
  • 2例患者对治疗产生轻微缓解,开始仑伐替尼后不久(1至2个月)远处转移肿瘤病灶出现结构退缩;1例患者达到疾病稳定,但未出现RECIST部分缓解。
  • 仑伐替尼开始后总生存分别为2、6、7个月;疲劳和高血压突出,1例患者在仑伐替尼治疗期间发生肺栓塞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为单中心回顾性分析,仅3例患者接受仑伐替尼治疗。
  • 观察到的获益短暂,毒性突出。
  • 作者指出需要临床试验来更好地明确仑伐替尼在晚期甲状腺未分化癌管理中的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Historical anaplastic thyroid cancer (ATC) outcomes have been terrible, with a median survival of only five months and <20% one-year survival. Improved outcomes are now achieved with aggressive initial therapy in stages IVA and IVB disease, but patients with distant metastatic disease (stage IVC) still do poorly; improved therapies are sorely needed. Kinase inhibitors have emerged as promising agents in the therapy of advanced medullary and differentiated thyroid cancer, but there are limited data regarding the use of lenvatinib in ATC. The aim of this study was to delineate clinical outcomes in a series of patients with advanced ATC in response to lenvatinib therapy. METHODS: A retrospective analysis was conducted involving all lenvatinib-treated Mayo Clinic ATC patients in 2015. RESULTS: Of 28 distinct ATC patients seen in 2015, three (11%) with metastatic disease of ECOG performance status 2-3 were treated with lenvatinib. Two patients were male; age range at ATC diagnosis was 57-84 years. All three patients attained successful local control of their disease with surgery and/or combined chemoradiotherapy. Lenvatinib was offered as the second, third, or fourth line of therapy at the time of metastatic disease progression. Two patients incurred minor responses to therapy, with structural regression of distant metastatic tumor disease soon after starting lenvatinib treatment (at one to two months), while one patient achieved stable disease, but no Response Evaluation Criteria In Solid Tumors partial responses resulted. Overall survival after starting lenvatinib was two, six, and seven months. Fatigue and hypertension were prominent, and one patient developed pulmonary emboli while on lenvatinib. CONCLUSION: This initial single-institution experience suggests that lenvatinib may have some disease-modifying activity in metastatic ATC that is otherwise refractory to cytotoxic chemotherapy. Unfortunately, observed benefits were transient, and toxicities were prominent. Clinical trials are required to ascertain better the utility of lenvatinib in the management of advanced ATC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Iñiguez-Ariza NM, Ryder MM, Hilger CR, et al. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. Thyroid. 2017. PMID: 28471306. doi:10.1089/thy.2016.0627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。